GLOBE Medicare drug pricing model faces its first legal test
PhRMA's Oct. 7 lawsuit against CMS puts the Part B most-favored-nation demonstration on a court calendar, forcing hospital pharmacy and finance leaders into dual-track budgeting for 2027 and 2028.
The GLOBE Medicare drug pricing model moved from policy debate to federal docket on Oct. 7, 2026, when PhRMA filed suit in Washington, D.C. against CMS, arguing the agency exceeded its statutory authority in building a mandatory Part B demonstration around international reference prices. For health system pharmacy and finance leaders, the filing does something more immediate than settle a constitutional question. It puts a live court calendar underneath the reimbursement benchmarks that buy-and-bill economics, GPO terms and payer escalators were all written against.
Source: CMS newsroom and fact sheets. Cycle 3 is the first cycle to include Part B drugs. Total selected to date: 40.
| Value (drugs selected) | Drugs selected |
|---|---|
| Cycle 1 (prices effective 2026) | 10 drugs selected |
| Cycle 2 (prices effective 2027) | 15 drugs selected |
| Cycle 3 (prices effective 2028) | 15 drugs selected |
What PhRMA is actually challenging
GLOBE is structured as a Part B pilot that tests the administration's most-favored-nation concept by benchmarking US payment to prices paid in other developed countries. That concept is not new. What is new, and what makes the litigation consequential for providers, is the shift from voluntary manufacturer agreements into a compulsory Medicare payment model. PhRMA's complaint, covered same-day by STAT News, Endpoints News and Bloomberg Law, centers on whether CMS has the statutory authority to run a demonstration of that scope and mandate.
The outcome matrix is narrow but the operational consequences differ sharply. If the model survives, Part B payment rates for affected products reset on the model's schedule. If a court enjoins or vacates it, the rates do not move, but the planning work already sunk into reconfiguring fee schedules and contract language does not come back. Neither scenario is remote enough to ignore, which is the core problem for anyone trying to close a 2027 budget.
Buy-and-bill margin assumptions, GPO terms and payer escalators were all written against benchmarks that may not survive the court calendar.
Three cost shocks hitting Part B at once
GLOBE is not arriving alone. Section 232 pharmaceutical tariffs imposed a 100% ad valorem duty on patented pharmaceuticals and biologics, effective July 31, 2026 for companies named in Annex III of the April 2, 2026 proclamation and Sept. 29, 2026 for all other importers. Commerce published implementation guidance in the Federal Register on Sept. 23, 2026 covering specialty pharmaceutical adjustments, urgent-health-need exclusions and Commerce-approved onshoring agreements carrying lower rates. Those exclusions matter operationally, because two therapeutically similar products can now land at very different acquisition costs based on where the manufacturer sits in the tariff structure.
The third track is IRA negotiation. CMS selected 15 drugs on Jan. 27, 2026 for the third cycle, the first to include Part B drugs, with negotiated prices effective in 2028. AJMC reported in early October that Trulicity and Botox are among them. Taken together, a single Part B infusion line can now be exposed to a tariff-driven acquisition increase, a negotiated maximum fair price and an international reference benchmark, on three different clocks, with only one of them under litigation.
Why a single 2027-2028 Part B budget no longer works
Pharmacy and finance leaders should stop trying to produce one number. The practical approach is dual-track modeling: a base case that assumes GLOBE proceeds on its stated schedule, and an alternative that assumes an injunction or vacatur holds current benchmarks in place. Each track should carry its own margin assumptions for the highest-spend buy-and-bill products, its own 340B spread estimate and its own contribution-margin floor by service line.
The contracting exposure is larger than the budgeting exposure. GPO terms, payer contract escalators and employed-physician infusion economics were largely negotiated against reimbursement benchmarks that may not survive the court calendar. Contracts renewing in the next two cycles need language that contemplates a mid-term benchmark change rather than assuming stability. That is a legal and managed-care task, not a pharmacy task, and it needs to start before a ruling lands.
Operations inherits the rest. Any benchmark change requires fee schedule updates, charge master revisions and claims-logic changes, potentially on short notice and potentially reversible. CIOs and revenue cycle leaders should know now which systems carry hard-coded Part B payment logic and how long a change takes to test and deploy.
Supply-side fragility compounds the planning problem
The pipeline side offers no cushion. The Fierce Biotech Layoff Tracker, updated Oct. 7, 2026, logged Caribou halting a pipeline program and Foghorn cutting 40% of staff in the first week of October alone. Repricing pressure and tariff costs land on an industry already trimming programs, which raises the odds that some therapeutic categories thin out rather than expand.
For health systems, that argues for scenario work on continuity as well as cost. Formulary committees should flag Part B products where a single manufacturer or a single tariff-exposed supply chain carries the category, and identify the therapeutic alternatives before a shortage or a withdrawal forces a decision under pressure.
